Literature DB >> 7014208

Clinical and hormonal aspects of the watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome due to vasoactive intestinal polypeptide (VIP)-producing tumor.

K Yamaguchi, K Abe, I Adachi, M Tanaka, M Ueda, Y Oka, S Miyakawa, T Kameya, N Yanaihara.   

Abstract

Three patients with the watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome were studied. All had watery diarrhea, hypokalemia and hypercalcemia. Plasma vasoactive intestinal polypeptide (VIP) levels determined by radioimmunoassay were markedly elevated in these patients, indicating that they had VIP-producing tumors. Plasma VIP levels determined serially after the operation indicate that its determination is useful in estimating the effect of a treatment. As for multiple endocrine neoplasia type 1 (MEN1), two out of the three cases belonged to this category. Patient 1 had a brother with insulinoma, and in case 2, even though there was no family history, the autopsy revealed not only multiple tumors of the pancreas but also pituitary adenomas, chief cell hyperplasia of the parathyroid glands, thyroid adenomas and adrenocortical adenomas. VIP and other hormones in the tumors as well as in the plasma were examined extensively in these cases. In case 1, VIP, gastrin and calcitonin were produced in the tumor and only plasma VIP levels were elevated. In case 2, with multiple tumors, tumor 1 produced VIP, glucagon pancreatic polypeptide, gastrin and calcitonin, and tumor 2, VIP, pancreatic polypeptide, gastrin and beta-melanocyte stimulating hormone. In this case, plasma VIP, pancreatic polypeptide and glucagon levels were elevated. In case 3, VIP and calcitonin were produced in the tumor, and plasma VIP and calcitonin levels were elevated. These results indicate that (1) VIP is a good tumor marker for the WDHA syndrome due to VIP-producing tumors; (2) patients with the WDHA syndrome are sometimes associated with MEN1; and (3) VIP-producing tumors are multiple hormone-producing tumors, and VIP predominantly elevated in the plasma results in the WDHA syndrome, although other hormones such as pancreatic polypeptide, glucagon and calcitonin are sometimes found to be elevated in plasma without contributing to the clinical features.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7014208     DOI: 10.1507/endocrj1954.27.supplement_79

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  2 in total

Review 1.  Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.

Authors:  Silvia Uccella; Annika Blank; Roberta Maragliano; Fausto Sessa; Aurel Perren; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

2.  GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1.

Authors:  Vinaya Srirangam Nadhamuni; Donato Iacovazzo; Jane Evanson; Anju Sahdev; Jacqueline Trouillas; Lorraine McAndrew; Tom R Kurzawinski; David Bryant; Khalid Hussain; Satya Bhattacharya; Márta Korbonits
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.